We conclude that loss of SMARCB1 expression in human PTCL largely occurs via somatic mutation and/or epigenetic silencing, whereas germline SMARCB1 mutations have not yet been observed in all samples tested. The gene discussed is SMARCB1; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.